Openbookopenbook
Equity
EKF
+0.0 · +0.00%
GBX · LSE

EKF Diagnostics Holdings Plc(EKF) Stock Analysis | Healthcare

GBX --+0.00%
Reward60Moderate
Risk20Low
75%Data
Thin 4% profit margin
Quality Compounder
Market Cap:108.82M
ⓘ
Reward Rating
60
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
20
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on EKF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for EKF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 35p.

What is EKF Diagnostics Holdings Plc?

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally.

EKF · Verdict

Solid reward · low risk

EKF scores well on balance sheet and volatility with no major weaknesses flagged in the model.

Based on 88% data coverage

EKF · Verdict

What’s working & what to watch

Strengths 4

  • Balance sheet99/100

    Interest covered 45.5×

  • Volatility80/100

    Top decile vs peers

  • Cash flow71/100

    16% free-cash-flow margin

  • Valuation70/100

    P/E 35.0× · PEG 3.02

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is EKF Diagnostics Holdings Plc?

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 108.82M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

AOTIMicro Cap / 106M market cap
AOTI Inc
Compare
MXCTMicro Cap / 162M market cap
MaxCyte Inc
Compare
NIOXMicro Cap / 285M market cap
NIOX Group PLC
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap108.82M
P/E RatioN/A
Dividend YieldN/A
Beta0.5
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.